12.63
-0.15 (-1.17%)
| Penutupan Terdahulu | 12.78 |
| Buka | 12.69 |
| Jumlah Dagangan | 1,428,957 |
| Purata Dagangan (3B) | 1,443,861 |
| Modal Pasaran | 1,167,011,968 |
| Harga / Pendapatan (P/E Ke hadapan) | 14.01 |
| Harga / Jualan (P/S) | 0.410 |
| Harga / Buku (P/B) | 2.03 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Nov 2025 |
| Margin Keuntungan | -29.43% |
| Margin Operasi (TTM) | -3.81% |
| EPS Cair (TTM) | -8.39 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -1.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 149.92% |
| Nisbah Semasa (MRQ) | 0.970 |
| Aliran Tunai Operasi (OCF TTM) | 164.20 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 310.66 M |
| Pulangan Atas Aset (ROA TTM) | -1.74% |
| Pulangan Atas Ekuiti (ROE TTM) | -61.58% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Fortrea Holdings Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | -3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 4.0 |
| Purata | 0.38 |
|
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 0.40% |
| % Dimiliki oleh Institusi | 101.90% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 11.00 (Evercore ISI Group, -12.91%) | Pegang |
| Median | 9.75 (-22.80%) | |
| Rendah | 9.00 (Mizuho, -28.74%) | Pegang |
| Purata | 9.88 (-21.77%) | |
| Jumlah | 3 Pegang, 1 Jual | |
| Harga Purata @ Panggilan | 10.17 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Barclays | 06 Nov 2025 | 10.00 (-20.82%) | Jual | 11.02 |
| 02 Oct 2025 | 8.00 (-36.66%) | Jual | 9.60 | |
| Mizuho | 17 Oct 2025 | 9.00 (-28.74%) | Pegang | 9.45 |
| Evercore ISI Group | 08 Oct 2025 | 11.00 (-12.91%) | Pegang | 10.13 |
| Jefferies | 09 Sep 2025 | 9.50 (-24.78%) | Pegang | 10.07 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 04 Dec 2025 | Pengumuman | SCTbio and Fortrea Forge Strategic Collaboration to Accelerate Cell and Gene Therapy Development and Delivery |
| 25 Nov 2025 | Pengumuman | Fortrea to Present at Upcoming Citi and Evercore Healthcare Conferences |
| 24 Nov 2025 | Pengumuman | Fortrea Completes $75.7 Million Senior Notes Tender Offer Utilizing Cash on Hand |
| 17 Nov 2025 | Pengumuman | Fortrea Appoints Agnieszka Gallagher as General Counsel |
| 05 Nov 2025 | Pengumuman | Fortrea Reports Third Quarter 2025 Results |
| 20 Oct 2025 | Pengumuman | Fortrea Announces Tender Offer for up to $75,744,000 Aggregate Purchase Price of Outstanding Debt |
| 15 Oct 2025 | Pengumuman | Fortrea Announces Date for Third Quarter 2025 Financial Results and Conference Call |
| 22 Sep 2025 | Pengumuman | Fortrea Appoints William Sharbaugh to Board of Directors |
| 12 Sep 2025 | Pengumuman | Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |